Switzerland · Delayed Price · Currency is CHF Addex Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Significant pipeline progress was made in chronic cough and brain injury recovery programs, with robust preclinical results and new clinical preparations. Financials show reduced cash burn and a cash runway through mid-2026, but further funding is needed for unpartnered programs.
-
Advanced GABAB PAM and Dipraglurant programs made significant preclinical progress, with robust efficacy data and strong patent positions. Cash runway extends to mid-2026, but further funding is needed for unpartnered clinical programs.
-
H1 2025 saw major pipeline progress, including IND-enabling studies for GABA-B PAM and M4 PAM programs, regained rights to mGluR2 PAM, and investment in Stalicla. Cash runway extends to mid-2026, but further funding is needed for unpartnered clinical programs.
-
Q1 2025 saw major pipeline progress, including IND-enabling studies for GABA-B PAMs and repositioning of dipraglurant for brain injury recovery. Cash runway extends to mid-2026, but further funding is needed for unpartnered clinical programs.
Fiscal Year 2024
-
Neurosterix spin-out secured CHF 5M and a 20% equity stake, reducing Addex's cash burn and funding overhang. GABAB PAM and dipraglurant programs advanced, with new clinical studies and partnerships planned. Cash runway extends to mid-2026.
-
GABA-B PAM programs advanced with a compound selected for substance use disorder and promising preclinical results in chronic cough. Q3 2024 saw lower income and expenses, with a strong cash position and continued R&D progress.
-
Neurosterix spin-out secured $63M, strengthening the balance sheet and enabling preclinical progress while retaining upside. GABAB PAM and dipraglurant programs advanced, with IND-enabling studies planned for 2025. Q2 2024 saw stable expenses and a CHF 3.8M cash position.
-
Advanced GABAB PAM and dipraglurant programs, secured CHF 5M and a 20% stake via Neurosterix spin-out, and maintained stable R&D spending. Awaiting full data from Janssen's epilepsy study and preparing for multiple IND-enabling studies in H2 2024.